Table 2.
Prospective Trails of Bladder Preservation
| Trial | Phase/Design | Stage | Number | Radiation (Gy) | Neoadjuvant Chemotherapy |
Concurrent Chemotherapy |
Adjuvant Chemotherapy |
Complete Response |
Bladder intact survival |
5-yr Overall Survival |
Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BC2001 | III | T2–T4a | 360 | 55 of 64 | 5FU and Mitomycin | 48% | James, et al (19) |
||||
| RTOG 02–33 | Randomized phase II |
T2–4a | 93 | 40.3 + 24 | Paclitaxel/Cisplatin 5FU/Cisplatin |
Cisplatin gemcitabine paclitaxel x 4 |
72% Pac 62% 5FU |
67% paclitaxel 71% 5FU |
71% paclitaxel 75% 5FU |
Mitin, et al (24) |
|
| RTOG 99-06 | I/II | T2–T4a | 80 | 40.3 + 24 | Cisplatin + Paclitaxel | GC x 4 | 81 | 47% | 56% | Kaufman et al (23) |
|
| RTOG 97-06 | I/II | T2–T4a | 46 | 40.8 + 24 | Cisplatin | MCV x 3 | 74 | 47 (3 yr) | 61 (3 yr) | Hagan et al (6) |
|
| RTOG 95-06 | I/II | T2–T4a | 34 | 24 + 40 | Cisplatin + 5-FU | 67 | 66 (3 yr) | 83 (3 yr) | Kaufman et al. (22) |
||
| RTOG 89-03 | III | T2–T4a | 123 | 39.6 + 25.2 | MCV x 2 None |
Cisplatin | 61 51 |
36 40 |
49 48 |
Shipley et al (12) |
|
| RTOG 88-02 | II | T2–T4a | 91 | 39.6 + 25.2 | MCV x 2 | Cisplatin | 75 | 44 (4 yr) | 62 (4 yr) | Tester et al (7) |
|
| RTOG 85-12 | II | T2–T4 | 42 | 40 + 24 | Cisplatin | 66 | 52 | Tester et al (25) |
|||
| Erlangan | N/A | T1–T4 | 415 (89 T1) |
Median 54 (45–69.4) |
Various: cisplatin, carboplatin, cisplatin + 5-FU |
72 | 42 | 51% | Rodel et al (4) |
||
| MGH | N/A | T2–T4a | 106 | 39.6 + 25.2 | MCV x 2 | Cisplatin | 66 | 43 | 52 | Kachnic et al (11) |
|
| Paris | N/A | T2–T4 | 54 | 24 +20 | Cisplatin + 5-FU | 74 | 59 (3 yr) | Housset et al (53) |
|||
| Italy | N/A | T2–T4 | 121 | Median 65 (34–57) |
MCV x 2 | Cisplatin or carboplatin | 86 | 51 | 68 | Perdona et al (9) |